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52 Introduction 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic relapsing inflammatory bowel 
diseases (IBD) of unknown etiology, that affect 2.5 – 3 million people in Europe [1]. IBD 
affects children,adolescents, and adults, with a peak incidence between 15 and 34 years [2,3].  
Diarrhea, bloody stools, and stomach pain are characteristic symptoms. The disease course 
is characterized by periods with symptom flares and periods of remission [3,2,4,5], but it is 
highly individual and variable, even in individual patients at different times during their 
illness. A high proportion of patients is on lifelong medication regimens and need frequent 
contact with the health care system [6]. Medical treatment includes the use of anti-
inflammatory medications, but these may cause adverse drug reactions. The symptom severity,
an unpredictable disease course, adverse drug reactions, loss of bowel control and knowing 
that the disease has no cure, may cause significant daily challenges and impact health-related 
quality of life (HRQOL) [7-12].Thus, living with a chronic illness such as IBD involves 
complex cognitive, physical, emotional, psychological, and behavioral processes [13].
Patients must manage and adjust to life-long medication use, lifestyle changes,find meaning 
in and adapt to unstable life conditions, relate to concerns about how their life will unfold, and 
discover how they can remain as healthy as possible [14].
Several studies have addressed  use of complementary and alternative medicine (CAM) 
among IBD patients [15]. CAM involves several therapies, products, and practices that are 
not normally part of conventional health care. Research has shown that IBD patients use 
CAM for reasons such as symptom relief, to ameliorate adverse drug reactions from 
conventional medicine, and to gain control over their disease [15]. However, CAM use is not 
unique to IBD patients. Systematic reviews have documented that the use of CAM has 
increased in the industrialized western world in recent decades, and it is currently regarded as 
common among the general population [16,17]. The Norwegian population spent a total of 
approximately 3.8 billion NOK on alternative practitioners in 2012 [18]. CAM use has rarely 
been assessed in non-selected IBD populations internationally, and the frequency of CAM use 
among IBD patients in Norway is not known. 
Fatigue has been identified as one of the leading concerns for IBD patients [11,19,20]. 
Studies assessing fatigue in IBD have found that it is a common experience, even 
6when the disease is quiescent [21-23] and that fatigue is associated with reduced HRQOL 
[24,25]. Although fatigue is common among IBD patients, the interference of fatigue with 
daily living has not been systematically investigated. Further, fatigue is a common reason for 
CAM use in other chronic diseases [26,27]. This relationship has not been adequately studied 
in the IBD population.  
Adjustment to chronic disease such as IBD is affected by different psychosocial factors. The 
medical sociologist Aaron Antonovsky studied why some people are able to stay healthy 
despite hardship and strain [28]. His answer was the concept “sense of coherence” (SOC): 
people who assess the world as meaningful, understandable, and manageable seem to adjust 
better to their situation and are healthier than those who not. In addition, a person’s belief 
about how capable he/she is to do what is needed to influence own health and deal with 
challenges (self-efficacy) has been related to self-management [29-31]. Thus, given the 
complexity of living with a chronic disease, personal resources appear to be important for 
well-being, quality of life, and the ability to cope with disease.
73 Aims of the thesis 
The overall aim of this thesis was to increase the knowledge about certain aspects of living 
with inflammatory bowel disease: the use of CAM, the experience of fatigue interference with 
daily living, sense of coherence and self-efficacy. The specific aims were: 
1. To determine the proportion of CAM use in a population based cohort of IBD patients
followed for ten years and to describe the associations between CAM use and socio-
demographic and disease-related factors (paper I) 
2. To determine the overall and specific use of CAM among IBD patients attending
outpatient clinics in Norway and to describe the associations between CAM use and socio-
demographic and disease-related factors (paper II).  
3. To examine fatigue interference with daily living in IBD patients, to explore the
relationships between severe fatigue interference and socio-demographic and disease-
related factors, as well as CAM use (paper III). 
4. To describe the sense of coherence among IBD patients and to explore the
relationships between socio-demographic and disease-related factors, fatigue interference, 
self-efficacy, and SOC (paper IV). 
84 Background 
4.1 Inflammatory bowel diseases   
Inflammatory bowel diseases are characterized by chronic, relapsing inflammation of the 
gastrointestinal tract. The two main entities are ulcerative colitis and Crohn’s disease, which 
differ in localization and behavior. UC is characterized by mucosal inflammation of the colon,
affecting the rectum and a variable extent of the colon in continuity [32]. CD is characterized 
by transmural and granulomatous inflammation that can be located at any site in the 
gastrointestinal tract from the mouth to the anus. The transmural inflammation in CD may 
cause a more mutilating disease behavior, with complications such as strictures, abscesses, 
and fistulas [33]. The diagnoses are confirmed by a combination of specific clinical, 
endoscopic, histological, and radiological criteria [34]. Both UC and CD can be complicated 
by extra-intestinal manifestations, which most commonly affect the joints, skin, eyes, liver 
and bile ducts [35]. In both diseases, inflammation causes intestinal symptoms, such as 
frequent and urgent diarrhea, sometimes with blood, pus, mucus, abdominal pain, tenesmus, 
and general symptoms including fever, fatigue, and weight loss [3,2].
4.1.1 Epidemiology and etiology 
In adults, the highest incidences of CD and UC have been reported in northern Europe and 
North America [36]. The latest incidence rates in Norway are 5.8 per 100,000 persons/year for 
CD and 13.6 per 100,000 persons/year for UC in the IBSEN study performed from 1990-1993 
[3,2]. The prevalence of CD in Europe is 213 cases per 100,000 persons, whereas the 
prevalence for UC is 294 cases per 100,000 persons [1]. Incidence has been increasing in
recent decades especially for CD and in the pediatric population. Changes in dietary habits
and environmental factors, such as improved sanitation and industrialization toward a western
lifestyle, are some of the explanations postulated [37,36]. The prevalence of IBD is expected 
to increase further due to the early age of onset of the disease and the low mortality of IBD
patients [36]. CD most frequently presents between 15 and 25 years of age, whereas UC most
frequently presents between 25 and 34 years [2,3].
The etiology and pathogenesis of the diseases are not well understood. Genetic, microbial,
and environmental factors are believed to play a role in the dysregulation of intestinal
immunity, leading to gastrointestinal injury [38,39]. 
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		demonstrated a genetic predisposition for IBD, although more 
so in CD than in UC [40-44]. Environmental factors, such as changes in diet, antibiotic use, 
cigarette smoking, hygiene status, microbial exposures, and pollution, have been proposed 
as potential triggering factors and are associated with an increased westernized lifestyle 
worldwide [45,46]. However, causality between environmental factors and development of 
IBD has not been established.  
4.1.2 Disease course 
Crohn’s disease
Defining specific disease phenotypes in CD is important for research constancy, patient 
management, and the assessment of disease prognosis. Several sub-classification systems 
have been used to classify CD. The most common are the Vienna classification [47] and the 
Montreal classification [48]. Disease location seems to remain stable over time, whereas 
disease behavior changes with an increasing number of patients progressing from non-
penetrating, non-structuring disease to stricturing or penetrating disease [49]. Population-
based studies have demonstrated that approximately one third of patients experienced a 
relapse within the last year and underwent intestinal surgery within the first five years [50,8].
After 20 years, the cumulative surgery rates lie between 40% and 80% [51]. Stenoses, fistulas, 
and abscesses are the primary reasons for bowel resection. Approximately  25%-46% of 
patients will experience extra-intestinal manifestations [50]. CD patients have an increased 
risk for colorectal cancer and small bowel cancer [52]. In a Norwegian population based-
study (the IBSEN study), there was no significant difference in the overall mortality between 
CD patients twenty years after initial diagnosis and the general population [53]. 
Ulcerative colitis 
In the Montreal classification, UC are sub-classified into three categories according to disease 
extent. Ulcerative proctitis is involvement limited to the rectum, left-sided colitis is 
involvement limited up to the splenic flexure, and pancolitis/extensive colitis involvement 
extends proximal to the splenic flexure [48]. Originating in the rectum, the inflammation may 
progress proximally during the disease course [4]. Severity of flares and their response to 
treatment vary from minor symptoms to life-threatening fulminant colitis that does not 
respond to treatment and requires colectomy. Approximately one third experience a relapse 
within a year [9]. Extensive colitis at diagnosis is an important risk factor for colectomy, and 
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the probability of colectomy is highest during the first year after diagnosis. Approximately 10 
% of patients undergo colectomy within the first ten years since diagnosis [4]. During the 
disease course, extra-intestinal manifestations are observed in approximately one third of 
patients [54]. A possible increased risk of colorectal cancer among UC patients is debated, but 
the most recent studies have shown a decreasing trend during the last decade [55]. New 
therapeutic options and the implementation of surveillance strategies may be some of the 
causes of the reduction [55]. The overall mortality risk is not increased compared to the 
general population [56]. 
4.1.3 Medical and surgical treatment  
The main treatment goals are to induce and maintain disease remission and improve HRQOL 
[6]. To promote a European perspective on the management of IBD, the European Crohn’s 
and Colitis Organisation (ECCO) has developed consensus guidelines [57-60]. Medical 
treatment is directed by several factors: type of disease, localization of lesions, severity, 
clinical predictors of severe disease course, complications, and medical response and 
tolerance of the patient [58,57]. The inflammatory manifestations of UC and CD are mostly 
treated with a spectrum of the same medications, including 5-aminosalicylic acid (5-ASA), 
corticosteroids, immunosuppressive agents, biological agents, and antibiotics.  
5-ASA has a central role in the treatment of UC, particularly in patients with mild to 
moderately active disease [57]. In addition, it is used as a maintenance treatment to sustain 
remission [57]. 5-ASA is still used to some extent in CD treatment, but the clinical rationale 
and documentation for this is weak [58,61]. 
Corticosteroid has a central place in the treatment of acute active UC and CD. Prednisolone 
has an immediate effect in 70 %-90% of the patients. Corticosteroids are not an option in 
maintenance therapy, because of serious long-term adverse effects, such as osteoporosis, 
increased risk for infections, and myopathy. The corticosteroid budesonide is an option when 
the inflammation is located in the terminal ileum in CD [61,62].  
The thiopurines azathiopurine (AZA) and 6-mercaptopurine (6-MP) are the most common 
immunomodulating agents used to maintain remission in UC and CD. Due to their slow 
onsets of action, they are not an option for single therapy in disease relapse.  Thiopurines are 
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also used in combination with anti-TNF therapy [62]. Methotrexate (MTX) is an 
immunomodulating agent introduced to CD patients who are resistant or intolerant to 
thiopurines, and it is effective at both inducing and maintaining remission. The role of MTX 
in the induction or maintenance of remission in UC has not been addressed [62]. Cyclosporine 
is an option in the treatment of patients with severe UC who do not respond to corticosteroids 
and are considered for urgent colectomy. The effect of cyclosporine in the treatment of CD 
has not been documented [61].  
Antibiotics are used to treat secondary complications in IBD, such as fistulizing disease 
[58,61]  
Tumor necrosis factor-α (TNF-α) is an important pro-inflammatory cytokine known to be 
important in the immune pathogenesis in IBD. TNF-α inhibitors neutralize the biological 
effect of the cytokine. Several different anti-TNF agents are available and they are commonly 
introduced to IBD patients with moderate to severe disease that are not responding to other 
therapies, have experienced serious adverse drug reactions, or who are not eligible for surgery 
[61].  
Medical treatments for IBD may have adverse effects. General adverse effects, such as 
nausea, stomach pain, tenesmus, diarrhea, skin rash, and fatigue are reported in relation to all 
the medication types and are difficult to differentiate from disease symptoms.  However, in 
most cases these adverse effects cease upon withdrawal of the drug. Treatment with 
corticosteroids may induce short-term adverse effects, such as fluid retention and weight gain, 
hypertension, high blood glucose levels, and sleep and mood disturbances. Among the long 
term adverse effects are increased risk for infections, osteoporosis, cataracts, and muscle 
atrophy. Use of immunosuppressants can affect the skin, liver, kidneys, pancreas, and cause 
malignancy, bone marrow suppression, and leucopenia. These risks increase with 
accumulated doses, and thus, patients need to be monitored for leucopenia with regular blood-
count measurements. Patients treated with anti-TNF have an increased risk for infections, but 
the risk for cancer is unclear. Allergic reactions under infusion may occur [61,62].  
In addition, iron deficiency and anemia are reported to occur frequently in both UC and CD 
[63-65]. Monitoring IBD patient hemoglobin levels, hematological status, iron status, vitamin 
12
12, and folic acid levels are recommended in the ECCO guidelines for the management of 
disease [59].
Surgery is performed in cases of medical treatment failure, during acute severe disease or if 
high-grade dysplasia is present [60]. In UC, proctocolectomy with ileal-pouch-anal- 
anastomosis (IPAA) is the procedure of choice for most patients requiring colectomy [60].
Surgery in CD may include small bowel resections and treatment of fistulas and abscesses 
[58].
4.1.4 Psychosocial support  
ECCO consensus guidelines states that psychosocial consequences of living with IBD should 
be taken into account during the regular clinical practice. Adequate time at consultancy, 
individual education of patients, patient-centered information, patient education programs and 
work with health-promoting strategies are suggested methods to meet these patient needs 
[6,59,60]. Nurses with special competence in IBD are suggested to have a key role in this 
work [66-68]. Recently, the N-ECCO (Nurses-European Crohn’s & Colitis Organisation) 
proposed statements for the nursing role in caring for IBD patients [68].
4.2 Core Concepts 
4.2.1 Complementary and alternative medicine 
In the western world and in the academic literature the term complementary and alternative 
medicine (CAM) is the most commonly used term to cover health care practices and products 
used primarily outside the formal health care system [69]. Subcategories of health-care 
seeking behaviors fall under the umbrella of CAM, such as the use of CAM services, which 
includes visits to alternative health care providers such as, acupuncture, homeopathy, spiritual 
healing, and reflexology, the use of CAM products such as, herbal medicine and dietary 
supplements, and different types of CAM self-help practices such as, yoga, meditation and 
relaxation techniques [70].  
CAM is heterogeneous, and this is exemplified by the national legal status and regulation of 
alternative health care providers and the terminology used. In most countries, CAM is not 
covered by national insurance systems, and users pay almost all costs out of pocket. In 
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addition, CAM constantly changes as some CAM modalities gradually become accepted and 
integrated into conventional medicine. For example, chiropractors are authorized health care 
personnel in Norway but not in Sweden. In contrast, naprapaths are authorized personnel in 
Sweden but not in Norway [71]. Further, although acupuncture is not legalized in Norway, it 
is accepted as a treatment in 50% of Norwegian hospitals [72]. Hence, the individual CAM 
modality that is included as CAM relies on tradition, culture, and context [73,74,71]. In 
addition, the term CAM includes two mutually exclusive terms: “complementary”, which 
indicates CAM modalities that are used alongside conventional medicine, and “alternative”,
which indicates CAM modalities that are used instead of conventional medicine. Moreover,
the term CAM borrows terminology from conventional medicine. Therefore, CAM is 
simultaneously comparable to conventional medicine while defined as something completely 
different [75]. Research on CAM is affected by the lack of a universal agreement on how it 
should be defined.
In Norway, alternative treatment is regulated by law. In § 2, in Lov om alternativ behandling 
[Alternative treatment act of illness] alternative treatment is defined as:  
“Alternative treatment is understood to mean health-related treatment which is 
practiced outside the established health services and which is not practised by 
authorised health personnel. However, treatment practised within the scope of the 
established health services or by authorised health personnel is also covered by the 
term alternative treatment when the methods used are essentially methods that are used 
outside the established health services” [76,77]. 
CAM subcategories are generally based on several different theoretical models. However, 
unifying aspects within CAM therapies, products, and practices are that the primary 
explanation of illness is a disturbance in an individual’s energy balance. Different traditions 
use different names for this, such as Qi, energy, prana, yin-yang, or dynamis [78]. This 
balance is understood as crucial for self-healing and the ability to regenerate [79]. CAM 
practitioners often hold a holistic view of health, emphasizing that health is a product of 
biological, psychological, social, and spiritual dimensions. Emphasis in treatment is often 
placed on individual resources and efforts. An important therapeutic element is the quality 
of the interaction and the communication between the patients and the therapist [71,80].  
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4.2.2 Fatigue and fatigue interference   
Fatigue is defined as a “sense of physical tiredness and lack of energy, distinct from sadness 
or weakness” [81]. The etiology of fatigue is poorly understood, but it is considered to be a 
subjective experience embracing physical, cognitive, as well as affective components [21]. It 
is associated with a sense of loss of control over one’s environment, low positive affect, and 
psychological distress [82]. Hence, fatigue interference of daily living is an important aspect 
of the fatigue experience. The Fatigue Severity Scale used in this dissertation was developed 
with the aim of measuring the impact of fatigue on daily living, i.e., fatigue interference [83]. 
4.2.3 Sense of Coherence 
The medical sociologist Aaron Antonovsky raised the question of why some people stay 
healthy despite stressful situations while others do not. To respond to the question he 
introduced the concept of sense of coherence (SOC) in his theory of Salutogenesis in 1979 
[84,28]. The concept “salutogenesis” originates from the Latin salus, which means health, and 
the Greek genesis, which means origin. Together, this term signifies the creation of health. 
Health is regarded as a continuum, a movement between total ill health (dis-ease) and total 
health (ease) rather than healthy versus unhealthy [85]. This positive health approach focuses 
on predictors for a positive health outcome.  
According to Antonovsky, the SOC concept reflects a person’s resources and dispositional 
orientation, which enables them to manage tension, reflect on internal and external resources, 
and deal with stressors in a health-promoting manner [86]. The resources are any 
characteristic of a person and their environment, such as personal control, self-identity, 
culture, social support, and socio-economic status [87]. SOC consists of a cognitive 
component (comprehensibility), a behavioral component (manageability) and a motivational 
component (meaningfulness) [85]. The stronger  the SOC, the more likely the person will 
assess the situation as understandable and predictable (comprehensibility), to have the 
resources and capacity to manage the situation (manageability) and to be motivated to move 
in a health promoting direction (meaningfulness) [85]. To measure one’s SOC, Antonovsky 
developed the Sense of Coherence questionnaire [88,89]. Systematic reviews on SOC 
research conclude that the SOC is strongly related to a person’s mental health and HRQOL 
[86,90]. Antonovsky assumed that a person’s SOC develops from life experience during 
15 
childhood and young adulthood, and to be relatively stable around the age of 30 [28]. 
However, intervention program research focusing on salutogenic treatment principles has 
shown that SOC is positively affected by interventions [85,91].  
4.2.4 Self-efficacy 
Self-efficacy is a core concept in Albert Bandura’s social-cognitive theory [29]. In the context 
of this theory, individuals are simultaneously agents and objects. We are proactive, reflective, 
and self-regulative and can influence our actions. Self-efficacy refers to the “ belief in one’s 
capabilities to organize and execute the courses of action required to produce a given 
attainment” [29] (p 3). In other words, self-efficacy is belief in one’s ability to succeed in a 
particular situation. Self-efficacy develops from early childhood through the experience of 
positive outcomes from one’s behavior and personal agency in situations. The reactions in 
one’s environment can promote or inhibit self-efficacy. Self-efficacy continues to evolve 
throughout life as people acquire new skills, experiences, and understanding. A review article 
evaluating intervention programs focusing on modifying a person’s self-efficacy concluded 
that enhanced self-efficacy could be of importance for improving chronic illness outcome, 
such as adherence to prescribed medical regimens and improved health status. Thus, self-
efficacy may serve as a predictor for health-related behavior and self-management [92].  
4.3  Previous research 
4.3.1 CAM use in the general population and in IBD patients 
CAM use in the general population  
In Norway, the use of CAM in the general population has been documented several times in 
the past 25 years [93-95,18,96]. The prevalence rates in these studies are difficult to compare 
due to the variability of CAM modalities included in the studies. However, in this period the 
use of CAM services (defined as receiving alternative therapy from a CAM practitioner, such 
as acupuncturist, homeopath, or healer) increased from 8% to 37% [95,93,94,18,96]. The 
latest study was conducted in 2012 by the National Research Center for Complementary and 
Alternative medicine (NAFKAM). They found no significant changes in the prevalence of 
CAM service use from 2007 to 2012 [18], and thus, the prevalence appears to have stabilized. 
This trend is comparable to Scandinavian countries and other western countries [97-99,17].   
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Acupuncture and massage are the CAM modalities most frequently reported in Norway 
[18,96,94], and the majority use CAM for symptom relief or to promote health [94]. Fifty 
percent of the Norwegian hospitals and one-third of the Danish hospitals offer alternative 
therapies [72]. In both countries, acupuncture was the most common CAM modality offered. 
In the NAFKAM study in 2012, the use of self- help practices (e.g., relaxation techniques, 
yoga, Qigong, and mediation ) and CAM products (e.g., herbal medicine) were defined as 
CAM [18]. When these CAM modalities were included as CAM, the overall CAM use was 
45.3  % [18]. In the general population, a persistent finding is that CAM users are more likely 
female, have a higher education level, are middle-aged, and report poorer health statuses than 
non-users [17]. 
CAM use among IBD patients 
In IBD, CAM use has been assessed largely in selected patient populations, such as hospital-
based samples or patients from patient self-help organizations. Data from non-selected 
population studies are rare. From 1995 to 2013, the reported current or past CAM use in 
North-America and Europe ranged from 21% [100] to 56 % [101]. There is a large variation 
in the types of services, products, and techniques that are included as CAM. The more CAM 
modalities included in the questionnaire, the higher the prevalence rates. Some studies include 
only CAM services (e.g., acupuncturist, homeopath, and healer) [102], some include CAM 
services and CAM products (e.g., herbal medicine, homeopathic remedies, and dietary 
supplements) [103-111], and the majority include CAM services, CAM products and CAM 
self-help practices (e.g., relaxation techniques, yoga, Qigong, and mediation) [101,112-
115,100,116-118]. Two studies assessed oral products only [119,120]. Visiting a homeopath 
is reported more often in European studies than in studies from North America [15]. This may 
suggest that, although the overall prevalence of CAM use seems to be similar across North 
America and Europe, the preferred form of CAM varies by region. 
A review of CAM use in IBD patients found that the reasons for CAM use fit into two broad 
categories: 1) direct disease-related benefits, indicating concerns regarding conventional 
treatment, including perceived lack of effectiveness and fear of side-effects; and 2) indirect
non-disease related benefits, 	ndicating the subjective benefits from CAM therapies and 
products, the desire to take personal responsibility for treatment, and the hope to gain a 
greater sense of control over one’s owns health care [15]. Whether CAM was utilized for IBD 
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symptoms, or other health problems or well-being was reported in some studies, but not 
others. The majority of patients used CAM alongside conventional medicine rather than 
replacing it [15]. 
The main socio-demographic characteristics associated with CAM use among IBD patients 
are female gender, younger age, and higher education level. These findings are in accordance 
with other chronic diseases [121,27,122,123]. Many disease-related factors have been linked 
to the use of CAM: hospitalization rates, extra-intestinal complications, experience of adverse 
effects in response to conventional IBD medications, immunosuppressant use, systemic 
steroid intake, comorbid chronic conditions, disease severity, and disease duration 
[110,111,101,104,115,102,113,118]. Three studies have assessed the relationship between 
CAM use and HRQOL. One reported that CAM users had lower scores on emotional and 
social dimensions compared to non-users [108], whereas no difference between CAM users 
and non-users was found in the two other studies [103,101]. An overview of the main studies 
that have evaluated IBD patients CAM use and the factors associated with CAM use are 
depicted in Appendix. 
4.3.2 Fatigue among IBD patients  
Fatigue has gained increased attention in IBD research over the last decade, and two 
systematic reviews have been published [21,7]. Several questionnaires have been used to 
assess fatigue prevalence in the IBD population. Fatigue has been conceptualized as a 
multidimensional phenomenon, and most of the studies refer to different dimensions of 
fatigue, including physical, cognitive, emotional and functional axes [7]. In addition, one 
study examined chronic fatigue [23]. The prevalence of fatigue among IBD patients in 
remission varies between 22 %–41 % and in moderate to active disease between 44 %– 86 % 
[7]. The association between severity of fatigue and severity of disease symptoms has been 
reported in several studies, but the association between fatigue and factors, such as gender, 
disease duration, anemia, and sleep quality has shown conflicting results [7]. Chronic fatigue 
has been found to be associated with impaired HRQOL and increased disease-related 
worrying [25,20]. One qualitative study used focus group interviews to explore the experience 
of fatigue among IBD patients and how they managed their fatigue in everyday life [124]. The 
patients experienced fatigue as a disabling effect on their social and emotional well-being,
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which limited their employment opportunities. However, the experience of fatigue 
interference with daily living has not been systematically measured in an IBD population. 
4.3.3 Sense of coherence and self-efficacy in IBD patients 
Personal factors, such as SOC and self-efficacy, have not gained much attention in IBD 
research. A few studies have assessed SOC in IBD patients [125-129].  Oxelmark et al. [125] 
included the SOC questionnaire as an outcome variable to evaluate a medical and 
psychosocial group-based educational intervention program with the aim of strengthening the 
coping ability of IBD patients. No significant increases in SOC scores were seen when 
comparing the intervention group before and after completion of the program, after 6 or and 
12 months. In another study by Oxelmark, SOC was evaluated in UC patients taking part in a
cancer surveillance program. The results showed that the UC patients’ SOC scores were 
comparable with healthy controls [129]. The General Self-Efficacy scale was included in a 
study with the aim of assessing the role and impact of stigma in IBD. Perceived stigma was 
found to be a significant predictor for decreased self-efficacy [130]. Keefer et al. [131] 
developed the IBD self-efficacy scale, which assesses four disease-related domains: managing 
stress and emotions, managing medical care, managing symptoms and disease, and 
maintaining remission. The psychometric test of the scale showed high reliability and validity. 
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5 Material and methods  
5.1 Research design 
The studies included in this thesis have a cross-sectional and descriptive design. Two 
different patient populations are included: one population-based sample and one outpatient -
based sample. The reason for including two patient populations was two-fold. First, no 
studies had reported CAM use in a population-based IBD cohort, and the frequency of CAM 
use among IBD patients in Norway was not known. The Inflammatory Bowel South Eastern 
Norway (IBSEN) study included a few questions about CAM use in the ten-year follow up 
(Paper I). Secondly, because the IBSEN study had few, and no standardized questions about 
CAM use, a new cross-sectional study was designed to more extensively evaluate CAM use 
in Norwegian IBD patients. In addition, we wanted to assess psychosocial factors, such as 
fatigue interference, SOC and self-efficacy (Papers II, III, and IV).  
5.2 Study populations 
5.2.1 The population-based sample  
The Inflammatory Bowel South Eastern Norway (IBSEN) study is a prospective, population-
based inception cohort. Between 1 January 1990 and 31 December 1993, all newly diagnosed 
cases of IBD in the south-eastern Norway (the counties of Oslo, Østfold, Telemark and Aust 
Agder) were registered in the inception cohort. On January 1, 1992, the total study population 
in these areas was 966, 427. The organization of the study included collaboration between 15 
hospitals and 1,236 general practitioners. All the participating hospitals followed strict 
guidelines for case definitions which followed internationally accepted criteria [34,132].
Endoscopy was the main instrument of diagnosis and determination of the extent of disease. 
A total of 843 patients were included in the original cohort. Further details about the 
organization of the cohort are described by Moum et al. [133].
Prescheduled follow-ups were performed at one, five, and ten years after enrollment in the 
cohort. At each follow-up visit, the patients underwent a clinical interview and a clinical 
examination by a gastroenterologist. In addition, blood samples were collected, and a 
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colonoscopy was performed upon patient consent. At the five-and ten-year visits, a patient-
reported questionnaire was included, and in the ten-year visit, questions about the use of 
alternative therapies for their IBD were included in the questionnaire. The patients completed 
the questionnaire at the hospital, prior to the clinical interview.  
In paper I, we used cross-sectional data from the ten-year follow up. The collection of data 
for the ten-year follow up took place from 1 January 2000 to 31 December 2004.  
Socio-demographic data 
The included socio-demographic variables were age (continuous variable), gender, and 
highest completed education (dichotomized as ≤12 years; maximum upper secondary school 
vs. >12 years; college/university degree).  
Clinical data  
Disease location and disease behavior in CD patients were classified according to the Vienna 
classification system [47]. There was no classification system for CD when the IBSEN study 
was started; therefore, this classification was performed retrospectively. At the ten-year 
follow up, the Vienna classification was the standard classification system, and the patients 
were classified prospectively. UC patients were classified into three subgroups by disease 
extent: proctitis (inflammatory changes up to 15 cm from the anus); left-sided colitis 
(inflammatory changes up to the splenic flexure; extensive (inflammation above the splenic 
flexure).  
Relapse was defined as an aggravation of symptoms resulting in more aggressive medical 
treatment or surgery. Surgery was defined as any intra-abdominal procedure for the treatment 
of active CD and was recorded as yes/no from diagnosis to the relevant follow-up visit. 
However, incisions and drainage of perianal abscesses and simple perianal fistulectomies did 
not qualify as surgery in this outcome definition. Colectomy status was recorded 
consecutively for UC patients.  
Medical therapies included the use of 5-ASA, azathioprine, and systemic steroids. The study 
was initiated before immunomodulators were widely used as maintenance therapy for UC and 
before anti-TNF therapy were generally introduced to IBD patients.  
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Clinical course of the disease 
The patients were asked to categorize the clinical course of their disease from the time of 
diagnosis to the present ten-year follow up according to four predefined curves, each 
reflecting a different disease pattern in terms of the severity of bowel symptoms: 1) remission 
or mild severity of intestinal symptoms after initial high activity, 2) increase in the severity of 
intestinal symptoms after initial low activity, 3) chronic continuous activity or 4) chronic 
intermittent activity.   
Questions regarding CAM use 
Questions regarding CAM were included in the patient reported questionnaire at the ten-year 
follow up. The questions were restricted to the use of CAM for IBD symptoms and included 
any of three therapies listed: 1) homeopathy, 2) acupuncture and 3) a healer. In addition, 
patients could specify other therapies they had used in a comment field. CAM use was 
defined as: 1) ever used CAM (any use of CAM in the ten years since diagnosis); 2) recently 
used CAM (any use of CAM during the six months prior to follow up); and 3) regular use of 
CAM (the use of CAM more than four times or regularly in the previous six months). The 
patients were also asked to assess their satisfaction with the CAM treatment they had used by 
providing one out of four possible scores: not at all satisfied, somewhat satisfied, mostly 
satisfied, and very satisfied.   
5.2.2 The outpatient-based sample 
The outpatient-based sample was collected by inviting 14 	
		hospitals
from the counties of Rogaland, Vest-Agder, Aust-Agder, Telemark, Oslo, Østfold, Hedmark, 
Oppland and Hordaland including eastern, western, and southern Norway. The patients were 
recruited during a regular visit to the 	
		. Patients aged ≥18 years old with a 
previously verified diagnosis of CD or UC that was confirmed clinically, endoscopically and 
histologically were eligible for inclusion in the study. The recruitment period was between 1 
October 2009 and 31 June 2011.
A booklet was made to collect both clinical and self-reported data. At each hospital, either a 
study nurse or a gastroenterologist was in charge of the study protocol. Clinical data were 
obtained from medical records by the health professional responsible for the enrollment and 
included diagnosis, classification of disease location and behavior, disease duration, current 
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medical therapy, and previous surgery for IBD. The disease activity scores (HBAI and 
SCCAI) were completed under clinical consultation. Self-reported data included socio-
demographic status, any experience with adverse drug reactions to IBD medication, 
comorbidities, CAM use, the five-item Fatigue Severity Scale, the General Self-Efficacy 
Scale, and the 13-item Sense of Coherence questionnaire. The booklet was completed at the 
hospital, but patients were also given the option to complete the questionnaires at home and 
return the booklet in a stamped addressed envelope.  
Socio-demographic data 
Socio-demographic data included age (continuous variable), gender, educational level (12 
years education or less [secondary] vs. more than 12 years [college/university education]); 
civil status (married or cohabitant vs. single, divorced, or partnered but living separately), 
work status (working including being a student vs. not working, including pensioner and work 
disabled); income (<25, 000 €/year, 25,000-45, 000€/year, 45,000-65,000 €/year, or >65,000 
€/year); place of residence (city vs. rural area) and smoking status (yes, defined as once or 
more daily vs. no). 
Clinical data 
The Montreal classification was used to classify disease location and behavior in CD [48].
Previous surgery included all types of surgery related to IBD. A pre-defined list of 
comorbidities was presented for the respondents and included cardiovascular disease, 
diabetes, arthritis, arthralgia, asthma, dermatological disease, and cancer. In addition, the 
respondents could add comorbidities not queried. In addition, the patients were asked to state 
yes/no if they had experienced adverse drug reactions to conventional IBD medication in the 
past or currently. A pre-defined list was presented and included nausea, abdominal pain, 
diarrhea, headache, fever, weight gain, mood changes, joint pain, sleep disturbance, and skin 
itch. In addition, the respondents could add adverse drug reactions not queried.  
Disease activity was measured with the Harvey-Bradshaw activity index (HBAI) in CD 
patients [134] and with the simple clinical colitis activity index (SCCAI) in UC patients 
[135]. HBAI measures clinical symptoms over the last 24 hours based on five items: general 
well-being (scale range 0-4), abdominal pain (scale range 0-3), number of liquid stools per 
day, abdominal mass (scale range 0-3), and complications, including: arthralgia, uveitis, 
erythema nodosum, aphthous ulcers, pyoderma gangrenosum, anal fissure, new fistula, and 
23 
abscess (score one per item). SCCAI measures clinical symptoms over the last 24 hours and 
consists of scores for five criteria: bowel frequency (day) (score range 0-3), bowel frequency 
(night) (score range 0-2), urgency of defecation (score range 0-3), blood in stool (score range 
0-3), general well-being (score 0-4), and extra colonic features (score one per manifestation). 
International CAM Questionnaire 
The International CAM Questionnaire (I-CAM-Q) was used to assess CAM use [70]. I-CAM-
Q is a self-reported questionnaire and includes four main questions and a number of sub-
questions. In this study, we report the results from the four main questions: (1) visiting health 
care providers offering alternative therapies (physician, chiropractor, homeopath, 
acupuncturist, spiritual healer, reflexologist, kinesiologist, laser treatment, or other not 
queried), (2) complementary treatments received from physicians (MDs’) (manipulation, 
homeopathy, acupuncture, herbs, spiritual healer, or other not queried); (3) use of herbal 
medicine and dietary supplements (vitamins/minerals, homeopathic remedies, and other 
supplements) and, (4); use of self-help practices (meditation, yoga, Qigong, Tai Chi, 
relaxation techniques, visualization, attending healing ceremonies, pray for your own health, 
or other not queried). Respondents were asked to indicate whether they used a particular 
provider/health care product or self-help practice within the previous 12 months.  
Definition of a CAM user 
In this study, a CAM user was defined as someone who had visited an alternative health care 
provider and/or used CAM products and/or used self-help practices at least one time within 
the previous 12 months. In the I-CAM-Q questionnaire, the use of vitamins and minerals was 
queried. Vitamins and minerals are often recommended by physicians as a part of the 
treatment regimen for IBD patients. We did not ask if the vitamins and minerals were 
recommended by a physician. In Norway, the use of fish oils is recommended by Norwegian 
health authorities [136]. Consequently, in this study, patients who reported their CAM use to 
consist exclusively of vitamins/minerals or fish oil supplements were defined as non-users.  
Following the recommendations of Harris et al. [99], we reported estimated overall CAM use, 
estimated use of each CAM modality, and estimated use of the three CAM categories: CAM 
services (including visiting an alternative health care provider or alternative treatments 
received from physicians (MDs), CAM products and CAM self-help practices.  
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In our study, the respondents were asked to provide information if they used CAM alongside 
with (response option yes/no) or instead of conventional medicine (response option yes/no). 
Additionally, we asked the respondents to provide information about their sources of 
information regarding CAM: friend, newspaper, relatives, health care workers, internet, health 
food store, TV, or a CAM practitioner.
The five-item Fatigue Severity Scale 
The five-item Fatigue Severity Scale (FSS-5) assesses the experience of fatigue 
interference with daily living [137,138]. Each item is rated on a 7-point Likert-type scale 
ranging from 1 (disagree) to 7 (fully agree). The mean of the five item scores represents a 
continuous variable with values from 1.0 (no fatigue interference) to 7.0 (maximum fatigue 
interference). A higher score indicates higher fatigue interference. Mean scores Ӌ5 are 
considered indicative of severe fatigue interference [139]. The internal consistency for the 
FSS-5 is shown in Table I. 
The Sense of Coherence Questionnaire 
The 13-item version of the Sense of Coherence Scale (SOC-13) was used [28]. The SOC 
instrument has been translated into 33 languages in 32 countries and is regarded as applicable 
to all cultures [140]. SOC-13 measures the degree to which an individual views the world as 
comprehensible (5 items), manageable (4 items), and meaningful (4 items). The item scores 
are summed up by means of a 7-point Likert-type scale. The total score is the sum of the 
items, ranging from 13 to 91, and the sub-dimensions range from 5-35 (comprehensibility) 
and 4-28 (manageability and meaningfulness). Higher scores reflect a stronger SOC. The 
SOC-13 scale is reported to be a reliable and valid instrument [140,141], with reported 
internal consistency (Cronbach’s α) of 0.70 to 0.92. The internal consistency of the scale is 
shown in Table I.  
General elf-fficacy cale
The General Self-Efficacy Scale (GSE) [142] measures the strength of an individual’s belief 
in their ability to cope with difficult demands in life. In particular, it explicitly refers to 
personal agency, i.e. the belief that one's actions are responsible for successful outcomes. The 
GSE consists of 10 statements to which the respondent rates from 1 “completely agree” to 4 
“completely disagree”. The GSE total score is calculated by summing each individual score 
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(range 10 to 40). A higher score indicates a stronger self-efficacy. The GSE has been 
translated into several languages, including Norwegian [143].  The Cronbach’s α value is 
shown in Table I.  
Table I. Description and reliability of the FSS-5, the 13-item SOC questionnaire and the GSE
Instruments Article Scales/dimensions Response 
Scale
Items Range Cronbach’s alpha
All UC CD
5-item Fatigue 
Severity Scale 
(FSS-5)
III
and 
IV
- 7 point 
Scale
5 5-35 0.89 0.90 0.88
Sense of 
Coherence 
(SOC) IV
SOC total 
Comprehensibility
Manageability
Meaningfulness
7 point 
Scale
13
5
4
4
13-91
5-35
4-28
4-28
0.85
0.72
0.61
0.72
0.86
0.74
0.62
0.69
0.85
0.71
0.61
0.73
General Self-
Efficacy Scale 
(GSE) IV -
4 point 
Scale 10 10-40 0.90 0.90 0.90
5.3 Data analysis and statistical methods 
Univariate descriptive analyses were performed to assess the characteristics of the two study 
samples. Continuous variables with normal distributions were described with means and 
standard deviations. When the continuous variables had skewed distributions, they were 
described with medians and ranges. Crude differences between groups were assessed with the 
Chi-square (χ²) test for categorical data and independent samplest-test for continuous 
variables with normal distribution and the non-parametric Mann-Whitney U test for variables 
with skewed distributions. In paper 4, Pearson’s correlation coefficients were calculated to 
identify the strength and direction of the relationships between the SOC total and the three 
SOC sub-dimensions (dependent variables) and age, disease activity, disease duration, fatigue 
interference and self-efficacy (independent variables). The strength of the correlations was 
interpreted according to Cohen’s guidelines: a small association is r = 0.1 to 0.29, a moderate 
association is r = 0.3 to 0.49 and a large association is r = 0.50 to 1.0 [144].
In papers I, II, and III, we used logistic regression analyses to assess possible associations 
between the dependent variables: CAM users vs. non-CAM users (papers I and II); severe 
fatigue interference (FSS-5 ≥5) vs. no severe fatigue interference (FSS-5<5) (paper III) and 
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socio-demographic and clinical variables. In paper I, the variables that differed (p-value 
<0.15) between CAM users and non-CAM users were considered for inclusion in the 
multivariate analysis. he inclusion criteria for multivariate analysis was 
set to p-value <0.10 between CAM users and non-CAM users (paper II) and between those 
with and without severe fatigue interference (paper III). The strength of the association was 
expressed as an odds ratio (OR) with the 95% confidence interval. The significance level 
was set to 5%.  
In paper IV, multiple linear regression analyses were used to determine the associations 
between relevant socio-demographic variables, clinical variables, GSE, FSS-5 (independent 
variables) and SOC and its sub-dimensions (dependent variables). Variables with p-value < 
0.10 in bivariate analyses were entered into the multiple linear regression models. Socio-
demographic variables were included in step 1, clinical variables in step 2, fatigue 
interference in step 3, and self-efficacy in step 4. To compare the included variables, the 
strength of their association with the dependent variable was expressed with the standardized
beta coefficient. Age and gender were considered as possible confounders, and were 
consequently included in all multiple regression analyses. Because of multiple testing, the 
significance level was set to 1%. Cronbach’s alpha was used to assess the internal consistency 
of the instruments. A coefficient >0.70 is considered acceptable, >0.80 is good and >0.90 is 
excellent [145]. All analyses were performed using SPSS for Windows version 20.0 [146].  
Missing items in I-CAM-Q, FSS-5, 13-item SOC questionnaire and GSE 
In I-CAM-Q, all 430 respondents answered yes or no for some of the CAM modalities listed 
in the questionnaire. If the respondents ticked yes at one or more CAM modalities listed and 
left the rest blank, the blank answer was recorded as no. These respondents were included in 
the CAM user group. If the respondents ticked no for one or more of the CAM categories but 
did not tick yes for any of the other CAM modalities, they were included in the non-CAM 
user group. Some respondents left a CAM category completely open. In these cases, a missing 
value was recorded when the respondent did not tick either yes or no for any of the CAM 
modalities listed in that particular CAM category.  
Respondents with more than 50 % missing in the FSS-5, SOC-13, and GSE were excluded 
from the analyses. With less than 50 % missing items, the values were replaced by means of 
the items with valid responses.  
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5.4 Ethical issues 
The IBSEN study was approved by the Regional Committees for Medical and Health 
Research Ethics in Norway and the Norwegian data inspectorate.  
 
The outpatient-based study was approved by the Regional Committees for Medical and 
Health Research Ethics in Norway (reference number: S-00858b) and the internal data 
protection officer at Oslo University Hospital.  
 
The studies were conducted in accordance with the Helsinki declaration [147]. All patients 
received verbal and written information about the objective of the studies and their right to 
withdraw or restrict their data from analysis at any stage. They signed a written informed 
consent prior to being enrolled in the studies.  
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6 Results 
 
6.1 Study populations and flow charts  
Paper I present data from the IBSEN study. The study sample is depicted in Figure 1. Papers 
II, III, and IV presents data from a selected sample of patients attending outpatient clinics at 
Norwegian hospitals. The study samples are depicted in Figure 2.  
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Figure1. The population-based sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original IBSEN cohort  
 
843 patients enrolled from  
1 January 1990 to 31 December 1993 
Lost to follow up n = 65 
Completed the10 year 
follow-up 
n = 619 
UC n = 353 
Completed the hospital visit 
n= 588 
CD n = 164 
Dead n = 71 
Non IBD at last follow up  
n = 87 
<18 years n = 1 
Telephone interviews n = 18 
Hospital records n = 13 
Completed the  
CAM questionnaire 
n = 517 
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                              Figure 2. The outpatient-based sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion period between 1 October 
2009 and 31 June 2011  
 
Signed informed consent  
n = 460 
 
Did not return the 
questionnaire 
n = 30 
Completed questionnaires 
n = 430 
 UC n = 190 
 
CD n = 240 UC n = 190 
 
CD n = 238 
 
Included sample in  
Articles III and IV  
n = 428 
Included sample in  
Article II  
n = 430 
Did not complete 
FSS-5, GSE and 
SOC n = 2 
Completed the 
questionnaire at 
home 
n = 62 
Completed the 
questionnaire at the 
hospital 
n = 368 
31 
 
6.2 Summary of results (papers I-IV) 
 
Paper I 
Background: The aims of paper I were to determine the proportions of CAM use in a 
population-based cohort of IBD patients followed for ten years and to describe the 
associations between CAM use and socio-demographic and disease-related factors.  
 
Results: Thirty percent of the IBD patients reported that they had used CAM for their IBD at 
some point in the ten-year period since the initial diagnosis, 7.5% reported current CAM use, 
and 3.1% reported regular use. A higher proportion of CD patients compared to UC patients 
reported CAM use (38% vs. 27%, respectively; p=0.01). The most frequently used CAM 
therapy was homeopathy (64% of the CAM users).  
 
The multivariate analyses revealed that younger age was independently associated with CAM 
use in both disease groups (CD, adjusted OR [adjOR] 0.96, 95% CI: 0.93-0.99 and UC, 
adjOR 0.95, 95% CI: 0.95-1.00), and it was the only factor independently related to CAM use 
in the CD group. In the UC group, female gender (adjOR 2.14, 95% CI: 1.23-3.73) and higher 
education level (adjOR 1.95, 95% CI: 1.12-3.37) were also independently associated with 
CAM use. Further, CAM users were mostly satisfied or very satisfied with the treatment. 
 
Conclusion: One third of the IBD patients had seen a CAM provider in the ten-year period 
since diagnosis, although very few used these modalities currently and regularly. Because 
only three CAM modalities were assessed, there is a possibility that our results are 
underestimated. Younger age was independently associated with CAM use in both UC 
patients and CD patients. Disease-related variables were not associated with CAM use.  
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Paper II 
Background: To determine the overall and specific use of CAM among IBD patients 
attending outpatient clinics in Norway and to describe associations between CAM use and 
socio-demographic and disease-related factors. 
 
Results: Of the 430 patients with evaluable questionnaires, forty-nine percent (95% CI: 44-
54) had used some type of CAM within the past 12 months. Twenty-seven percent (95% CI: 
23-31) had used CAM services (seeing a CAM provider). The most common single CAM 
service was acupuncture. Twenty-one percent (95% CI: 16-23) used CAM products, and 28% 
(95% CI: 23-31) used CAM self-help practices (relaxation techniques and praying for own 
health were the most frequently reported techniques). The most common pattern of CAM use 
involved a combination of CAM services and CAM products.  
 
A significantly higher proportion of UC patients reported CAM use compared to CD patients 
(55% versus 44%, respectively; p = 0.03). Among CD patients, the strongest factor 
independently associated with CAM use was experiencing adverse drug reactions from IBD 
medications (adjOR 3.23, 95% CI: 1.73-6.06). In addition, the socio-demographic factors of 
female gender (adjOR 2.43, 95% CI: 1.27-4.64), being aged 31-50 years (adjOR 2.32, 95% 
CI: 1.09-4.96), and having a higher education level (adjOR 2.11, 95% CI: 1.08-4.14) were 
independently associated with CAM use. Among UC patients, only the presence of at least 
one comorbid condition was independently associated with CAM use (adjOR 2.36, 95% CI: 
1.18-4.72). 
 
Conclusion: CAM use was common among IBD patients attending outpatient clinics at 
hospitals in Norway. Both demographic and disease-related variables were associated with 
CAM use among CD patients, while only disease-related variables were associated with CAM 
use among UC patients.  
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Paper III 
The aims of paper III were to examine fatigue interference with daily living in IBD patients 
and to explore relationships between severe fatigue interference, socio-demographic and 
disease-related variables, as well as use of CAM. 
 
Results: Patients attending outpatient clinics at Norwegian hospitals were invited to 
participate. Of the 428 patients with evaluable questionnaires (response rate 93%), severe 
fatigue interference was reported by 39 % of the total sample. CD patients (n=238) were more 
likely than UC patients (n=190) to report severe fatigue interference (43% and 33%, 
respectively; p=0.003). Patients reporting severe fatigue interference were more likely to have 
active disease than patients without severe fatigue interference (p<0.001 for both diagnoses). 
A significantly higher proportion of CAM users reported severe fatigue interference 
compared to non-users among UC patients with active disease. 
 
Multivariate regression analyses revealed that factors independently associated with severe 
fatigue interference in the UC group were disease activity (adjOR 4.32, 95% CI: 1.87 to 
10.02) and CAM use (adjOR 2.20, 95% CI: 1.09 to 4.44), while in the CD group, disease 
activity (adjOR 3.59, 95% CI: 1.81 to 7.13) and current smoking (adjOR 1.62, 95% CI: 0.83 
to 3.16) were independently associated with fatigue interference. 
 
Conclusion: Similar to other studies assessing fatigue in IBD populations, active disease was 
strongly associated with severe fatigue interference. CAM use was independently associated 
with severe fatigue interference among UC patients but not among CD patients.  
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Paper IV 
Background: The aim of paper IV was to explore associations between SOC and socio-
demographic, disease-related, and personal characteristics in a sample of patients with 
inflammatory bowel disease.   
 
Results: A total of 428 patients attending outpatient clinics (ulcerative colitis, n=190; Crohn’s 
disease, n=238) completed the questionnaires (response rate 93%). The overall mean SOC 
total score was 66.25 (SD 11.47). No significant differences were found in the SOC total or 
sub-dimension scores between UC patients and CD patients. In both disease groups, higher 
self-efficacy was positively associated with SOC, and fatigue interference was negatively 
associated with SOC. Socio-demographic and disease-related variables were not significantly 
associated with SOC after controlling for fatigue interference and self-efficacy in multiple 
regression analyses. 
 
Conclusion: Fatigue interference and self-efficacy contributed more to the variance in SOC 
than socio-demographic and disease-related variables. Longitudinal studies are warranted to 
investigate the value of SOC as a predictor of disability, medication adherence, coping 
behavior, and health-related quality of life. 
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7 Discussion 
7.1 Methodological considerations 
 
7.1.1 Generalizability 
The ability to generalize findings to a larger population contributes to the external validity of 
a study [148]. Representativeness is important for consideration of external validity. 
 
The population-based sample 
The main aim in paper I was to describe the proportion of CAM use in Norwegian IBD 
patients. The IBSEN study represents an unselected population-based IBD cohort. A non-
selected population is preferable because it is not biased by including the most ill patients, 
those who seek care through conventional medical providers, and those who are most 
comfortable within the framework of conventional medicine [15,106]. The IBSEN study has a 
prospective design, strict case ascertainment criteria, and the patients were included from four 
well-defined geographical counties in south eastern Norway with a uniform health care 
system. The ten-year follow-up rate was high, and the completion rate of the questionnaire 
was acceptable (83.5%). There were no significant differences with regard to age, gender, or 
type of diagnosis between the responders and the non-respondents. Thus, we may assume that 
the sample is representative of the general Norwegian IBD population. 
 
The outpatient-based sample 
The main aim of the cross-sectional descriptive study was to assess CAM use in a broader 
manner than was possible in the IBSEN study (paper II). In addition, we wanted to explore 
psychosocial factors related to patient management of their disease (papers III and IV). An 
outpatient-based IBD sample was chosen because the majority of the IBD patients are 
followed up at outpatient clinics at Norwegian hospitals. Further, we can approach the 
patients it is in clinical practice. The Norwegian health care system is divided into four health 
regions to provide specialized health services to the whole population [149]. To assure 
heterogeneity of the IBD sample, we recruited patients from small local hospitals, regional 
hospitals, and university hospitals in the two health regions covering southern, eastern, and 
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western Norway. Thus, the sample is representative of IBD patients attending outpatient 
clinics at hospitals in Norway.  
Four hundred and sixty patients provided their informed consent and were included in the 
study. Of these, thirty patients did not return the questionnaire after one reminder. Responders 
and non-responders were comparable with regard to their age, gender, disease duration, and 
type of diagnosis. A response rate of 93 % is considered high. However, the patients were 
included under a regular visit at their hospital. Only eight out of 14 hospitals included patients 
consecutively. The reason given for not including consecutive patients was lack of time under 
the consultations to introduce the questionnaire. In addition, no data were collected from the 
individuals who were approached but who chose not to participate. Further, a high proportion 
of the patients were currently treated with TNF-α inhibitors (60 % of the CD patients and 
44% of the UC patients), which corresponds well to the fact that a high proportion had severe 
disease. There is no data available of the proportion of patients on anti-TNF therapy in 
Norway, but this high use of anti-TNF therapy is likely not representative of the Norwegian 
IBD patients attending outpatient clinics. We assume that the reason for this selection bias is 
due to convenience; infliximab is administered intravenously over one to two hours and thus, 
these patients had the available time to complete the questionnaire. Convenience samples may 
be biased in that those who are included differ from those who were not approached or those 
who declined to participate. However, the study sample had a higher proportion of CD 
patients than UC patients, corresponding well to the fact that more CD patients require regular 
medical care than UC patients. With the relatively large sample sizes, (N = 430 for paper II / 
and N = 428 for papers III and IV, we believe that the description of the phenomena and the 
relationships between the dependent and independent variables at fixed points of time are 
representative of IBD patients attending outpatient clinics at Norwegian hospitals.  
Different methods of administering the questionnaire may also impact the results, as the 
patients choosing to complete the questionnaire at home differ from those who complete 
the questionnaire at the hospital. A significantly higher proportion of patients undergoing 
TNFα therapy completed the questionnaire at the hospital compared to those who completed 
the questionnaire at home (p=0.003 for the difference), in accordance with the observation 
that the high use of TNFα therapy was associated with logistical convenience at the 
hospitals. The patients who completed the questionnaire at home were comparable with those 
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completed the questionnaire at the hospital in regard to gender, age, education level, 
diagnosis, CAM use, fatigue interference, GSE scores, and SOC scores.  
The northern part of Norway is not represented in the two samples. It may be possible 
that this demographic area differs from southern Norway regarding CAM use, especially 
with regard to folk medicine, which is more commonly used in northern Norway.
Cross-sectional design 
In both studies, we used a cross-sectional design. In a cross-sectional design, the 
measurements of exposure and outcome are made at the same time. This makes it difficult to 
assess direction of the associations observed. However, cross-sectional studies indicate 
associations that may exist and are therefore useful in generating hypotheses for future 
research. 
7.1.2 Internal validity 
Internal validity refers to whether the conclusions drawn from the study population are valid 
[148]. Concerns of the internal validity in the present studies will be discussed. 
Information bias 
When recall time is long, information bias can occur. In the IBSEN study we asked about 
CAM use during the 10-year period since the initial diagnosis. It is highly possible that the 
patients used some form of CAM without remembering 10 years later. Consequently, we may 
have underestimated CAM use in this study. In the outpatient-based sample, the recall time 
was 12 months, thus it may have been easier to remember. However, when several CAM 
modalities are pre-defined for the patients, it may lead to false memories of using a modality 
one has used or think one has used. Hence, this may have led to an overestimation of CAM 
use in the outpatient- based sample. In addition, it is possible that questions of CAM use in a 
clinical setting, in which attitudes toward CAM may be unfavorable, may have caused bias 
towards an underestimation of true CAM use. 
Confounding 
A threat to the validity of associations in observational studies is referred to as confounding, 
i.e., when an association between two variables is fully or partly caused by a third factor
[148]. One way to address this is to correct for possible confounding variables by 
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multivariable statistical analysis. We chose to correct for gender and age in the multivariate 
analyses in all four studies. It is known from earlier studies in IBD populations that anxiety, 
depression, sleep disturbance, and anemia are associated with fatigue severity. We could not 
control for the possible confounding role of these factors in our study (paper III). 
Multicollinearity occurs when independent variables in a regression are so highly correlated 
that it becomes difficult to distinguish their individual effects on the dependent variable. 
Thus, multicollinearity can be viewed as a case of confounding, when the same variable is 
essentially entered into a regression model twice or when a variable contains exactly the same 
information as another variable. In paper IV, we assessed factors associated with SOC. None 
of the independent variables included in the final analyses were highly correlated (defined by 
Pearson correlation coefficient >0.7) with any other possible covariate.  
Reliability  
Reliability refers to the degree to which a questionnaire is free from errors of measurement 
and the consistency with which it obtains the same value at repeated measures [148].
In the population-based study, the questions about CAM use were not standardized or 
validated.  In the outpatient-based study, we used several questionnaires. The reliability of the 
questionnaires is discussed below.  
I-CAM-Q was developed by CAM researchers and practitioners brought together in an 
international workshop sponsored by the NAFKAM of the University of Tromsø, Norway 
[70]. Consensus regarding the definitions and international comparability between the 
questionnaires used to measure CAM are a much needed methodological improvements in the 
field of CAM research. I-CAM-Q was developed to provide an opportunity for researchers to 
gather comparable data in studies conducted in different populations, thus facilitating 
comparisons between studies [70]. When we carried out our study from 2009- 2011, no 
psychometric test of the I-CAM-Q had been conducted. Later, Eardley et al. [150] conducted 
a pilot feasibility study of I-CAM-Q in five European countries to assess the item wording 
and the design of the questionnaire [151]. The pilot study revealed problems with the layout, 
the terminology, and the response options. Respondents from all countries found the 
questionnaire hard to read and understand. This resulted in a high missing rate. Eardley et al. 
concluded that I-CAM-Q had low face validity indicating that it failed to subjectively cover 
the concept it purportedly measured [145].Additionally, a validation study of the I-CAM-Q 
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among breast cancer patients compared with the general population in Germany was 
conducted. The results from this study supported the low face validity and also found a high 
rate of missing. The highest missing rates were found in the questions regarding the frequency 
of use, reasons for use, and helpfulness of a CAM modality [151]. 
The pilot study by Eardley et al. and the German validation study sum up the problems we 
faced with I-CAM-Q. The rates of missing data in the questionnaire concerning the frequency 
of use, reasons for use, and helpfulness of health care service and self-help practice were 
substantial in our study, in accordance with the results from the two studies mentioned. We 
therefore decided to not use these data.  
With regard to the questions we used in the I-CAM-Q, the main limitation was due to 
terminology. I-CAM-Q provides no definitions of the CAM modalities queried. Therefore, the 
respondents had to know about a particular CAM modality to give a valid answer. We had to 
assume that respondents declared themselves as non-users of a particular CAM modality if 
they were not familiar with it. In addition, I-CAM-Q included physicians (MD) as health care 
providers. This option was included with the aim of comparing conventional health care use 
with CAM use. Our respondents were patients at regular hospital visits, and failure to include 
physicians (MD) would not be valid information in our study. Further, I-CAM-Q did not have 
questions on CAM use specifically related to a disease, and thus, we do not have data on how 
many patients used CAM specifically for IBD. In conclusion, further validation of I-CAM-Q
is needed before it can be used in future research. The results from our study should be 
interpreted in light of these limitations. 
The disease activity measurements SCCAI and the HBAI do not adequately evaluate disease 
activity in patients with a stoma, and the majority of studies choose to exclude this patient 
group when assessing disease activity scores with these disease activity indices. In our study, 
five UC patients and 20 CD patients had a stoma. The stoma patients in the UC group had a 
median SCCAI score of 6.5 (range 2-8). However, the median SCCAI score was 4 (range 0-
15), regardless of the inclusion of those with a stoma. The median HBAI score in the CD 
patients with a stoma was 6 (range 1-21), and the median HBAI score was 5 (range 0-15) 
regardless of the inclusion of those with a stoma. Therefore, we decided to include the stoma 
patients when assessing disease activity scores. 
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A short version of the original Fatigue Severity Scale (FSS) was used to assess fatigue 
interference. The choice of using the FSS-5 was based on results from studies using modern 
test theory (Rasch analysis). These studies showed inconsistent responses in the FSS, and they 
demonstrated that a five-item version of the FSS had better psychometric properties than the 
original nine-item version [137,138]. The five items query how fatigue interferes with daily 
living. In the introduction to the FSS-5, fatigue was defined as “being tired and weary and 
having lack of energy” [139]. Using classical test theory, the original FSS demonstrated good 
psychometric properties [152,153,83], and it has been validated in the Norwegian general 
population [139]. However, FSS-5 has not been validated in the Norwegian general 
population or in an IBD population. In our study, the reliability of the FSS-5 was measured in 
terms of internal consistency, which was found to be satisfactory (Cronbach’s α 0.89) [145]. 
No other studies of FSS-5 have reported a Cronbach’s α value. Further validation of the FSS-
5 should be performed before further use in studies.  
 
The General Self-Efficacy Scale was used to assess the IBD patients self-beliefs in coping 
with demands in life [142]. The internal consistency of the scale in our study was high 
(Cronbach’s α 0.90), which is considered excellent [145] and corresponds well with other 
Norwegian studies [154,155].  
 
The 13-item Sense of Coherence Scale was used to measure an individual’s orientation to life. 
The internal consistency of the total SOC score was satisfactory [145] (Crohnbach’s α 0.85) 
and corresponded well with other Norwegian studies [156,157]. We also assessed the SOC 
sub-dimensions. A coefficient above 0.70 is regarded as acceptable. In our study, the internal 
consistency at the sub-dimensions was 0.61-0.74. The Cronbach’s α value is a function of 
both the average inter-item correlation and the number of items in a scale, and it increases as 
either of these increases [145]. Thus, the lower values of the subscales may be because the 
scales consist of 4 and 5 items. 
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7.2 General discussion of the results 
7.2.1 CAM use  
The results from our studies revealed that CAM use was common among Norwegian IBD 
patients. Our results are congruent with results from previous IBD research, from other 
chronic illness groups as well as in the general population [17,15,16,18,122,123,26,158,159].
The CAM modalities measured in the two samples differed. In the IBSEN study, only three 
types of CAM modalities were predefined for the patients: homeopathy, acupuncture, and 
spiritual healer. In the outpatient-based study, CAM use included both CAM servicesCAM
products and CAM self-help practices. In addition, the IBSEN study asked for CAM use 
related to IBD symptoms, whereas this was not a question in the I-CAM-Q. Because of 
different CAM definitions and different time-frames (CAM use since diagnosis vs. the last 12
months), the proportion of CAM use cannot be compared between the two study samples in 
this thesis. This methodological difficulty is reported to be a common problem in CAM 
research and leads to great variation in prevalence rates. This is demonstrated in a systematic 
review of the prevalence of CAM use among general populations in Europe [16] reporting 
prevalence rates from 0.3 % to 86 %. Furthermore, due to the heterogeneity of the CAM 
modalities included, the data could not be pooled in a meta-analysis.  
CAM use in the population-based sample 
In the IBSEN study one third of the patients reported CAM use at some point since diagnosis.
The prevalence of current or past CAM use among IBD patients varies from 21 % to 56 % 
[100,113,111,112,108,106,107,115,105,101]. However, CAM use among IBD patients has 
rarely been reported in an unselected IBD sample, thus there are no direct comparable IBD 
studies. CAM use was more common among CD patients compared to UC patients in this 
population-based study. This finding is in contrast to other IBD studies, where comparable 
rates between the diagnoses are most often reported (Appendix). One possible explanation is 
that this is a population-based study, and CAM use specific to IBD symptoms was 
investigated.  
42 
 
Even though one third of the IBD patients had seen a CAM provider in the 10-year period 
since diagnosis, only 3.1 % had used CAM regularly during the previous six months. This 
may indicate that, despite the relative high use, consistent use is uncommon. This assumption 
is supported by a longitudinal study that measured CAM use among IBD patients over a 4.5 
year period: the overall CAM use was high (49 %), but only 14% used CAM consistently at 
every time point [103].  
CAM use in the outpatient-based sample 
In the outpatient-based sample, one third of IBD patients reported the use of CAM services at 
least once the last 12 months and acupuncture was most frequently used (10 %). Despite the 
limitations to I-CAM-Q  described above, our results are in accordance with the reported use 
of CAM services in the Norwegian general population, reported by NAFKAM in 2012 [18]. 
In Norway, acupuncture is the most frequently reported modality both inside and outside the 
government-funded health care system [96], and it is offered at 50 % of Norwegian hospitals 
[72]. Eight percent of patients had been seeing a chiropractor. A chiropractor is defined as a 
CAM service in several international IBD studies [15,103] and was one of the modalities 
listed in the I-CAM-Q. Despite the fact that chiropractors are authorized health personnel in 
Norway, we included chiropractors in the CAM services in our study. The use of CAM 
products and self-help practices was reported by 21 % and 28 % of the IBD patients in our 
study, respectively. Our results are higher than reported numbers in the Norwegian general 
population, where 11 % had used CAM products and 13 % had used self-help-practices 
within the last 12 months [18]. The differences found between the studies may be because a 
higher number of self-help practices were predefined in I-CAM-Q compared to the NAFKAM 
study. For example, prayer for one’s own health was included as a CAM modality in I-CAM-
Q, but not in the NAFKAM study. There is no common agreement on whether to classify 
prayer as CAM [160]. There is also a lack of a clear definition of the CAM modalities queried 
in both I-CAM-Q and the NAFKAM study [150]. Ten percent reported prayer in our study, 
and together with relaxation techniques this was the most common self-help practice. In a 
qualitative study, patients with chronic diseases were interviewed about their decision to use 
CAM [161]. The study revealed that many of the participants considered spiritual approaches 
to be an important element addressing the emotional effects of having a chronic disease. They 
claimed it helped to make sense of the world and gain a sense of control when faced with a 
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challenge such as chronic illness. Religious belief has also been found to be an important 
aspect of psychosocial needs in patients with cancer [162].  
 
The most common types of CAM services used by the IBD patients in both IBD study 
samples in this thesis, (homeopathy, acupuncture, chiropractic) also reflect the pattern of 
CAM services used in Europe, where the top five CAM modalities are herbal medicine, 
homeopathy, chiropractic, acupuncture and reflexology [16]. In this regard, patients appear to 
use CAM that is available and common in their culture. With the growth of more complex 
and culturally diverse societies, therapeutic options are likely to increase in number [163] and 
slowly integrate into the culture, although they may not be accepted as therapies in the formal 
health care system. The regional and cultural variation in CAM services, products, and 
practices worldwide suggests that a uniform profile of CAM use is unlikely. 
Factors associated with CAM use 
Female gender, a higher education level and younger and middle age were independently 
associated with CAM use in both the population-based sample and the outpatient-based 
sample. These socio-demographic variables have been found to be related to CAM use 
independent of the population studied (general populations or disease-specific populations) 
and the CAM definition used [17,164,16,165,102,15,119,122,123,166,158,97,121]. In 
general, women seek health care more often than men [167]. To our knowledge, no studies 
have further assessed the gender differences in CAM use among IBD patients. Several studies 
have shown that women report worse HRQoL scores compared to men in IBD populations 
[9,8,168]. There are contrasting findings between HRQoL and CAM use [108,103,101]. 
Compared to older patients, younger patients may be more likely to perceive the diagnosis as 
a threat to their future plans and may therefore be more willing to seek out available treatment 
options, including CAM. People with higher education are more resourceful in seeking out 
additional support for their illness and are more likely to be able to pay out-of-pocket for their 
health care [165,166]. However, income was not an independent factor associated with CAM 
use in our study. This may be due to relatively low levels of socio-economic inequality in 
Norway.  
 
In the outpatient-based sample, we found that disease-related factors were associated with 
CAM use. The presence of comorbidities was associated with CAM use among UC patients. 
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It is known from studies in the general population that those who use CAM more often have 
chronic health problems compared to those who do not use CAM [169,170]. Experiencing an 
adverse drug reaction to IBD medication was associated with CAM use in CD patients. Our 
finding is in line with that perceived lack of effectiveness of treatment and seeking help with 
adverse drug reactions to conventional medicine are of the most frequently stated reasons for 
seeking CAM among IBD patients [171].The association between CAM use and 
comorbidities and adverse drug reactions to IBD medications may suggest the IBD patients 
seek alternative therapies when conventional medicine not has a therapeutic option. In this 
case, CAM use is a self-management strategy for chronic illness [102]. Questions about 
comorbidity and adverse effects from IBD medication were not included in the IBSEN study 
hence we could not assess this relationship in the population-based sample.  
We may assume that a patient seeing a CAM provider differs from a patient who practices 
self-care, such as the use of CAM products and self-help practices. We did not ask why the 
patients used CAM nor did we ask for their health beliefs. This information is interesting 
because it is reasonable to assume that health beliefs and health care preferences will provide 
important information as to why they use or do not use CAM. Li et.al. [171] found that 
commonly stated reasons for CAM use among IBD patients were the subjective benefits 
experienced from CAM therapies and products (well-being), the wish to take personal 
responsibility for treatment, and the desire to gain a greater sense of control over their own 
health care. In contrast, those who found that conventional health care was successfully 
treating their disease and those who did not believe CAM to be effective did not use CAM. 
This may indicate that IBD patients seek CAM to promote health following their health 
beliefs. Health is an important and positive value in the modern western society [172]. To be 
concerned with and care for your own health has become the norm and may also be seen as a 
duty [172]. In addition to conventional medicine, there are many stakeholders, such as CAM 
providers, that help to improve health. Thus, it is possible to be pragmatic in the choice of 
health care [96]. The pragmatic health care user utilizes both conventional and alternative 
medicine in the management of health problems [173]. One reason IBD patients in Norway 
may be pragmatic in their search for health care, is that they can afford to pay for it. Norway 
provides health care services for all based on need and regardless of personal income. A
cross-cultural comparison between Norway and the United States, a country with low 
government expenditure on health showed that utilization of CAM practitioners was higher in 
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Norway compared to the United States [174].
7.2.2 Fatigue interference  
Several studies have identified fatigue as a common concern for IBD patients [175-178,11].
Our interest was to explore if fatigue interfered with physical functioning and with work, 
family, and social life. We found that 39 % of the IBD patient reported fatigue to severely 
interfere with daily living. Disease activity was the strongest independent factor related to 
severe fatigue interference. A strong association between fatigue and disease activity is 
common finding in IBD research [179,23,24,22,7], and it is assumed that inflammation 
processes play a role in the physiological etiology of fatigue [21]. Elevated disease activity is 
often associated with increased bowel movement, decreased general well-being, and stomach 
pain. Therefore, it is reasonable to assume that this may affect the patients’ energy capacity 
and interfere with their physical and social function. In addition, when fatigue is addressed in 
the clinical consultations, it is most often assessed in relation to physical aspects, such as 
anemia, which are assumed to contribute to fatigue in IBD [7]. If this is not the case, there are 
few therapeutic options for fatigued patients. The relatively large proportion of the IBD 
patients reporting fatigue to severely interfere with daily living indicates that fatigue may be 
best understood from a bio-psychosocial perspective. Depression and anxiety, sleep-
disturbance, malnutrition, and side effects from medical treatments, such as thiopurinesl,  in 
part explain the variance in fatigue in IBD [7]. In addition, psychosocial distress may be an 
important contributor to fatigue severity in chronic diseases such as IBD [180,22]. Except 
from the impact of thiopurines, these associations could not be elucidated in our study.  
We found an association between CAM use and fatigue interference in UC patients with 
active disease. Considering that many of the CAM services and practices have an underlying 
assumption that illness is a disturbance of an individual’s energy balance, it is perhaps not 
surprising that fatigued patients use these services and practices to try to improve energy 
levels. Elsenbruch et al., [181] found that UC patients in remission who participated in a ten 
week course that included mind-body therapies and diet showed significantly greater 
improvement in HRQOL scores (SF-36 and IBDQ) compared to a control group that got 
standard care. However, a systematic review of CAM interventions for management of 
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cancer-related fatigue found no support for their effectiveness, mainly due to poor quality 
research, heterogeneity in CAM modalities assessed, and a variety of outcome measures 
[182]. A challenge in conducting interventional studies regarding CAM is how to understand 
the outcome concept. To measure only direct biomedical outcomes (e.g., disease activity) has 
been criticized for being too narrow when evaluating complex interventions such as CAM 
[183]. The experience of fatigue is related to one’s perceived energy capacity. Hence, the 
choice of outcome measures in relation to fatigue must be able to detect health-related 
changes, including subjective experienced energy and well-being [184].  
 
In other disease groups, such as cancer, multiple sclerosis and rheumatoid arthritis 
psychosocial interventions (counseling, stress management, and coping strategies) have been 
found to be potentially beneficial in reducing fatigue levels [185,186]. In IBD, one newly 
published intervention trial which used a health promoting perspective (focusing on coping 
abilities of the patients rather than their problems), was effective at reducing fatigue and 
improving HRQOL in IBD patients with quiescent disease [187]. However, while a 
significant effect was observed after 3 months, the effect diminished after 9 months. Hence, a 
prolonged intervention period was proposed [187].  
 
7.2.3 Sense of coherence 
The socio-cognitive concept SOC is shown to be useful to evaluate the patient’s resources to 
cope with stressful situations such as chronic illness [91]. SOC has not been well evaluated in 
an IBD population. Therefore, to explore associations between SOC and socio-demographic, 
disease-related, and personal variables in an IBD population was an important first step. We 
found a strong association between SOC and general self-efficacy. Due to the cross-sectional 
design, we were unable to identify the direction of the association observed. Nevertheless, the 
results suggest that positive feelings, thoughts, and expectations (self-efficacy) contribute to a 
high SOC. Both SOC and self-efficacy have been found to be positively related to mental 
health and HRQOL in the general population and in other chronic diseases [86,155,90,156].  
Fatigue interference was associated with significantly lower SOC scores. The FSS-5 measures 
the intensity of fatigue interference with daily activities. We found that the higher the 
intensity the lower the SOC scores. The experience of fatigue is related not only to disease 
processes and physical conditions but also to general life circumstances [188]. A study of 
patients with chronic heart failure found a negative association between mental fatigue and 
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SOC [189]. The authors suggested that patients with a limited ability to understand and 
manage their situation may be more vulnerable and affected by mental fatigue. In our study, 
we were unable to identify the direction of the association observed due to the cross-sectional 
design.  
In addition to the SOC total score, the SOC sub-dimensions were explored in our study. 
Antonovsky’s intention was to use the SOC questionnaire as a measure of the whole and not 
to examine the three sub-dimensions separately [140]. However, there is an ongoing debate 
about the factor construction of the questionnaire. Factor analysis has confirmed the one-
factor solution proposed by Antonovsky in some studies, while other studies indicate between 
two and four sub-categories depending on the age of the studied population [140,190].To 
evaluate the factor construction of SOC in an IBD population, a population-based IBD sample 
would be the most appropriate.   
Antonovsky assumed that a person’s SOC develops from life experience during childhood 
and young adulthood and to stabilize around the age of 30. After that time, the SOC is 
relatively resistant to change [28]. However, a large body of research has demonstrated that 
the development of SOC is a life-long process, and consequently, the highest mean SOC 
values are seen among the elderly [140]. In our study, age ranged from 18-70 years, but we 
did not find support for increasing SOC scores with increasing age. However, our study 
included a selected sample of IBD patients. A population-based sample may be more 
appropriate to evaluate the association between age and SOC scores in IBD patients.  
Significant changes in SOC scores and improved coping as a result of interventions based on 
salutogenic treatment principles have been reported among patients with chronic illness 
[91,191].  One study found that manageability was most affected by intervention in people 
with mental health problems [91]. In another study, all SOC sub-dimensions changed 
significantly between baseline and a 12 month follow-up after a patient education course for 
people with morbid obesity [192]. SOC was used as an outcome measure to evaluate an 
integrated medical and psychological/psychosocial group-based intervention program for IBD 
patients. No significant increase in SOC was observed after completion of the intervention, or 
after six and twelve months [125]. The SOC scores in the IBD group were significantly higher 
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compared with the mental illness group and the obesity group [91,192].Thus, the high mean 
SOC scores at baseline may be one reason no increase in SOC was observed in the IBD study. 
However, results from the intervention studies mentioned above indicate that SOC may 
improve with therapy, education, and social support. 
 
7.2.4 Illness perception 
CAM use was common among IBD patients independent of the study sample or CAM 
definition used. IBD patients reported that fatigue severely interfered with daily living, 
including physical functioning, work, family, and social life. The experience of fatigue was 
negatively associated with SOC in both the UC and CD patients. These findings underscores 
that living with a chronic disease with an unpredictable course is challenging and patients 
need to find ways to adjust and maintain well-being and quality of life despite their illness. 
Unsuccessful adjustment may result in an experience of an uncontrollable situation and in 
enduring distress. In our study, we found some differences between UC and CD patients. For 
example, factors associated with CAM use differed, more CD patients reported severe fatigue 
interference, and CAM use was associated with fatigue interference only in the UC group 
with active disease. However, the UC and CD patients had comparable scores for SOC and 
self-efficacy. Hence, they did not differ with regard to personal recourses. To elaborate these 
observations further, knowledge about how IBD patients perceive their illness and its 
consequences may be important in order to understand how they relate to their illness and 
their health behavior. An individual’s illness perception form personal meaning to symptoms 
and disease and have been found to be important for the self-management of chronic illness 
[193]. Health professionals contribute to illness perception, as in cases where a medical 
diagnosis and its consequences are explained, but the interpretation of this information is 
highly individual [193]. Questionnaires that measure illness perceptions are available, such as 
the Illness Perception Questionnaire [194]. Studies assessing IBD patients’ illness perceptions 
have shown that low personal control over illness and believing in that IBD has serious 
consequences predicted psychological stress, poorer quality of life and reduced functional 
independence [195-197]. Longitudinal studies in other chronic diseases have shown that 
illness perceptions can change over time and are modifiable with education and psychosocial 
support [193]. Over time, living with a chronic disease can change the perception of 
consequences, emotional response, and control in light of the patient’s experience with 
chronic disease. Moreover, interventions, such as medical and psychological education 
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courses and psychosocial support, can give new insight into illness perceptions [198].  Thus, 
studies of UC and CD patients’ illness perceptions may provide important knowledge to use 
in health education courses aimed of improving coping and adaption to the symptoms and 
disease progression.  
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8 Summary  
8.1 Conclusions 
 In the population-based 
 one third of the IBD patients had used CAM atsome
point in the ten-year period since initial diagnosis, although few reportedCAM use
currently and regularly. The most frequently used CAM providers washomeopathy.
 Among UC patients, younger age, female gender, and higher education level were
independently associated with CAM use, whereas the only variable independently
associated with CAM use among CD patients was younger age.
 In the outpatient-based sample, one out of two IBD patients had used some type of
CAM the last 12 months. One third had used CAM services, one out of five had used
CAM products, and one third had used CAM self-help practices. Acupuncture, herbal
remedies, relaxation techniques, and prayer were the most frequently reported CAM
modalities.
 isease-related  were associated with CAM use in both UC and CD.
 Severe fatigue interference was common among IBD patients. Disease activity was the
strongest independent factor related to severe fatigue interference in both the UCgroup
and the CD group.
 CAM use was associated with severe fatigue interference among patients with the UC,
but not among those with CD.
 The mean total SOC score among IBD patients was comparable to estimated rates in
general populationV. In both UC and CD patients, self-efficacy was positively
associated with SOC while fatigue interference was negatively associated with SOC.
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8.2   Future perspectives  
CAM use seems to be is a part of the IBD patients’ self-management. The quality of doctor-
patient communication is important for allowing the patients to discuss their CAM use. 
Incorporation of CAM-related courses at nursing schools and in medical education will 
enhance the ability of these health care professionals to evaluate CAM.  
Population-based studies assessing CAM use are rare. The IBSEN 20 year follow-up has 
included several questions regarding CAM use, including reasons for use. The results may 
give a more comprehensive picture of CAM use in the IBD population. The results regarding 
the relationship between CAM use and HRQOL in IBD are inconclusive, and this needs to be 
further addressed in subsequent studies. Knowledge about why patients use CAM may 
provide important information about health beliefs, values, and patient expectations and will 
be important guidelines to understand self-management strategies [199,171].   
The usefulness of mind-body therapies aimed at reducing fatigue should be further 
investigated, preferable as a longitudinal intervention study.  
The value of SOC as an assessment of patient’s recourses to deal with stressors should be 
evaluated further. This could be achieved through an intervention study using salutogenetic 
principles with the aim of maintaining and stimulating the adjustment to illness. To further 
investigate the complex relationship between SOC, disease symptoms, and HRQOL, 
longitudinal studies are needed. 
Improving self-efficacy is addressed as one important goal of educational interventions for 
patients with chronic diseases [154]. In IBD, the IBD Self-Efficacy Scale [131] is 
recommended because it relates directly to self-management requirements unique for IBD 
patients. Therefore, the scale may be a useful tool in both clinical and research settings 
assessing the impact of personal resources in the management of IBD. Longitudinal studies 
are also warranted to investigate the value of SOC and self-efficacy as predictors of disability, 
medication adherence, HRQoL, and coping behavior in IBD patients. 
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Internasjonalt spørreskjema om bruk av komplementær og alternativ 
medisin (I-CAM-Q) 
 
 
 
Denne delen av spørreskjemaet omhandler din bruk og nytte av ulike 
komplementære og alternative behandlinger (KAM). 
 
 
Det er flere spørsmål knyttet til hver type behandlingsform.  
 
● Kryss av i listen over behandlinger, Ja for dem du har benyttet og Nei for dem du 
ikke har benyttet (sett kryss for hver behadling).  
 
● Hvis du svarer Ja: fyll ut hovedårsaken til at du oppsøkte behandleren eller benyttet 
behandlingsformen, og hvilken nytte du har hatt av dette. 
  
● Svarer du Nei, går du videre til neste behandlingsform.  
 
● I siste rute skriver du inn de komplementære og alternative behandlingsformene 
som du har benyttet, men som ikke er på listen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
NAFKAMs internasjonale KAM-spørreskjema (I-CAM-Q): 
 
 
1. Besøk hos behandlere: Forskjellige alternative behandlere og ansatte innen skolemedisin 
kan ta seg av helseproblemer.  
      
Har du vært hos en 
eller flere av 
følgende 
behandlere de 
siste 12 
månedene? 
 
N
ei
 
 
 Ja
 
 
 An
ta
ll 
ga
n
ge
r d
u 
va
r h
o
s 
de
nn
e
 b
e
ha
n
dl
er
en
 d
e 
si
st
e 
3 
m
ån
e
de
n
e
?  
Angi hovedårsaken til at du sist gikk til behandleren  
(Kun ett kryss). 
Hvor nyttig var det 
for deg å gå til 
denne 
behandleren? 
(Kun ett kryss) For en akutt 
sykdom/tilstand 
med varighet 
kortere enn én 
måned. 
 
For å 
behandle et 
langvarig 
helseproblem 
(varighet 
lenger enn én 
måned) eller 
symptomer 
knyttet til dette  
For økt 
velvære 
Annet 
(Vennligst spesifiser 
den andre årsaken) 
Ve
ld
ig
 n
yt
tig
   
 
 
 
 
Li
tt 
n
yt
tig
 
 Ik
ke
 n
yt
tig
 
 Ve
t i
kk
e  
 
Lege 
 
  
     
Kiropraktor 
 
  
     
Homøopat 
 
  
     
Akupunktør 
 
  
     
Healer 
 
  
     
Kinesiolog 
 
  
     
Soneterapeut 
      
Laser-
behandler 
      
Annen (skriv 
hvilken) 
 
 
  
     
 
 
 2 
INTERNASJONALT KAM - SPØRRESKJEMA 
 
2. Alternative behandlinger mottatt fra leger  
 
Hvis du ikke har vært til lege de siste 12 måneder, gå til spørsmål 3. 
Noen leger gir både alternativ og skolemedisinsk behandling  
 
Har du fått noen av 
følgende 
alternative/ 
komplementære 
behandlingsformer 
av en lege de siste 
12 månedene? 
 
N
ei
 
 
Ja
 
 
An
ta
ll 
ga
n
ge
r d
u 
fik
k 
de
nn
e
 
be
ha
n
dl
in
ge
n
 d
e 
si
st
e 
3 
m
ån
ed
en
e
 
Angi hovedårsaken til at du sist fikk denne behandlingen 
(Kun ett kryss)  
Hvor nyttig var det 
å få denne 
behandlingen fra 
legen?  
(kun ett kryss) 
For en akutt 
sykdom/tilstand 
med varighet 
kortere enn én 
måned 
For å 
behandle et 
langvarig 
helseproblem 
(varighet 
lenger enn én 
måned) eller 
symptomer 
knyttet til dette  
 
For økt 
velvære 
Annet 
(Vennligst spesifiser 
den andre årsaken) 
Ve
ld
ig
 n
yt
tig
 
 
 
Li
tt 
ny
tti
g 
 
 Ik
ke
 n
yt
tig
   
 
 Ve
t i
kk
e  
 
Manipulasjon 
 
  
     
Homøopati 
 
  
     
Akupunktur 
 
  
     
Urter 
 
  
     
Healing 
 
  
     
Annen (skriv 
hvilken): 
____________ 
 
  
     
 
 
 
 
 
 
 
 
 
 
 
 
 3 
QUANDT ET AL. 
3. Bruk av urtemedisin og kosttilskudd, inkludert tabletter, kapsler og 
flytende midler.   
 
For hver kategori nedenfor, 
skriv opp til tre produkter som 
du har brukt de siste 12 
månedene. 
 
Br
uk
er
 d
u 
di
ss
e
 
pr
od
uk
te
n
e
 n
å?
  Angi hovedårsaken til at du sist brukte dette produktet. 
(Kun ett kryss). 
Hvor nyttig var 
dette produktet for 
deg? 
(Kun ett kryss) For en akutt 
sykdom/tilstand 
med varighet 
kortere enn én 
måned 
 
 
For å 
behandle et 
langvarig 
helseproblem 
(varighet 
lenger enn én 
måned) eller 
symptomer 
knyttet til dette 
For økt 
velvære 
Annet 
(Vennligst spesifiser) 
Ve
ld
ig
 n
yt
tig
 
 
 
Li
tt 
ny
tti
g 
 
 Ik
ke
 n
yt
tig
   
 
 Ve
t i
kk
e  
 
Ja
 
 N
ei
 
Urter/urtemedisin 
________________ 
 
 
     
________________ 
 
 
     
________________  
 
 
     
Vitaminer/mineraler 
________________ 
 
 
     
________________  
 
 
     
________________ 
 
 
     
Homøopatiske midler 
________________  
 
 
     
________________  
 
 
     
________________  
 
 
     
Andre tilskudd 
________________ 
 
 
     
________________ 
 
 
     
________________ 
 
 
     
 
 4 
INTERNASJONALT KAM-SPØRRESKJEMA 
 
4. Selvhjelpsteknikker 
 
Har du brukt noen 
av følgende 
selvhjelps-
teknikker de siste 
12 månedene? 
N
ei
 
 
 Ja
 
 
 An
ta
ll 
ga
n
ge
r d
u 
ha
r 
br
uk
t 
de
nn
e
 te
kn
ik
ke
n 
de
 s
is
te
 
3 
m
ån
ed
en
e
? 
Angi hovedårsaken til at du sist brukte denne selvhjelpsteknikken. 
(Kun ett kryss) 
Hvor nyttig var 
denne 
selvhjelpsteknikken 
for deg? 
(Kun ett kryss) 
For en akutt 
sykdom/tilstand 
med varighet 
kortere enn én 
måned 
 
For å 
behandle et 
langvarig 
helseproblem 
(varighet 
lenger enn én 
måned) eller 
symptomer 
knyttet til dette  
 
For økt 
velvære 
Annet 
(Vennligst spesifiser 
den andre årsaken) 
Ve
ld
ig
 n
yt
tig
 
 
 
Li
tt 
ny
tti
g 
 
 Ik
ke
 n
yt
tig
   
 
 Ve
t i
kk
e  
 
Meditasjon 
 
  
     
Yoga 
 
  
     
Qigong 
 
  
     
Tai Chi 
 
  
     
Avspennings
-teknikker 
 
  
     
Visualisering 
 
  
     
Deltakelse i 
tradisjonell 
helbredelses-
seremoni 
 
  
     
Bønn for 
egen helse 
 
  
     
Annen (Skriv 
hvilken): 
___________ 
 
  
     
 
 
 
 
  
FATIGUE – FSS-5 
 
Skala for gradering av det å være sliten, uopplagt og ha mangel på overskudd. 
 
 
 
Instruksjon: Velg et tall fra 1 til 7 som angir i hvor stor grad du er enig med hvert enkelt 
utsagn, der 1 angir at du er helt uenig og 7 at du er helt enig.  Sett ring rundt ett tall for 
hvert utsagn. 
 
 
 Helt uenig 
 
Helt enig 
1 Jeg blir fort sliten og uopplagt. 
 
1 2 3 4 5 6 7 
2 Det at jeg er sliten og uopplagt, virker inn på 
hvordan jeg fungerer fysisk. 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
3 Det at jeg er sliten og uopplagt, skaper ofte 
vanskeligheter for meg. 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
4 Det at jeg er sliten og uopplagt, virker inn på 
evnen til å utføre visse oppgaver og plikter 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
5 Det at jeg er sliten og uopplagt, virker inn på 
mitt arbeid, mitt familieliv eller min omgang 
med venner og kjente. 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Opplevelse av sammenheng (OAS) 
 
1. Har du følelsen av at du egentlig ikke bryr deg om det som foregår rundt 
deg? 
 
 
Svært sjelden  
eller aldri  1 2 3 4 5 6 7  Svært ofte 
 
 
2. Har du noen gang blitt overrasket over oppførselen til folk du trodde du 
kjente godt? 
 
 
Aldri Skjedd  1 2 3 4 5 6 7  Alltid skjedd 
 
 
3. Har det skjedd at mennesker du stolte på har skuffet deg? 
 
 
Aldri skjedd  1 2 3 4 5 6 7  Alltid skjedd  
 
 
4. Hittil har ditt liv vært preget av 
 
           Svært klare 
Ingen klare mål og mening        mål og 
i det hele tatt  1 2 3 4 5 6 7  mening
            
            
 
 
5. Har du følelsen av å ha blitt urettferdig behandlet? 
 
 
Svært ofte  1 2 3 4 5 6 7  Aldri 
 
 
6. Har du følelsen av å være i en ukjent situasjon og ikke vite hva du skal 
gjøre? 
 
 
          Svært sjelden eller 
Svært ofte  1 2 3 4 5 6 7 aldri  
         
 
 
 
 
7. Dine daglige gjøremål er 
 
En kilde til  
dyp glede          En kilde til smerte 
og tilfredsstillelse 1 2 3 4 5 6 7 og kjedsomhet
             
   
8. Har du svært blandede følelser og ideer? 
           
          Svært sjelden eller 
Svært ofte  1 2 3 4 5 6 7 aldri  
         
   
 
 
9. Hender det at du har følelser du helst ikke ville hatt? 
 
 
          Svært sjelden eller 
Svært ofte  1 2 3 4 5 6 7 aldri  
           
 
 
10. Mange mennesker, selv de med sterk personlighet, føler seg noen 
ganger som ”tapere” i visse situasjoner. Hvor ofte har du følt deg slik? 
 
 
Aldri    1 2 3 4 5 6 7 Svært ofte  
 
 
11. Når noe har skjedd, har du stort sett følt at 
 
Du har overvurdert         Du vurderte   
eller undervurdert         tingene på riktig 
viktigheten av det 1 2 3 4 5 6 7 måte  
            
        
 
 
12. Hvor ofte føler du at dine daglige gjøremål har liten mening? 
          Svært sjelden eller 
Svært ofte  1 2 3 4 5 6 7 aldri  
          
 
 
13. Hvor ofte har du følelser du ikke er sikker på om du kan kontrollere? 
 
          Svært sjelden eller 
Svært ofte  1 2 3 4 5 6 7  aldri 
 
Mestringsforventning (GSE) 
 
Vennligst sett kryss ved de svarene som passer best for deg. 
(Ett kryss for hvert spørsmål) 
 
  Ikke 
riktig 
Litt  
riktig  
Nokså 
riktig 
Helt 
riktig 
  
▼ ▼ ▼ ▼ 
1. Jeg klarer alltid å løse vanskelige 
problemer hvis jeg prøver hardt nok 
 
□ □ □ □ 
2. Hvis noen motarbeider meg, så kan 
jeg finne måter og veier for å få det 
som jeg vil. 
 
□ □ □ □ 
3. Det er lett for meg å holde fast på 
planene mine og nå målene mine. 
 
□ □ □ □ 
4. Jeg føler meg trygg på at jeg vil 
kunne takle uventede hendelser på 
en effektiv måte. 
 
□ □ □ □ 
5. Takket være ressursene mine så 
vet jeg hvordan jeg skal takle 
uventede situasjoner. 
 
□ □ □ □ 
6. Jeg kan løse de fleste problemer 
hvis jeg går tilstrekkelig inn for det. 
 
□ □ □ □ 
7. Jeg beholder roen når jeg møter 
vanskeligheter fordi jeg stoler på 
mestringsevnen min. 
 
□ □ □ □ 
8. Når jeg møter et problem, så finner 
jeg vanligvis flere løsninger på det. 
 
□ □ □ □ 
9. Hvis jeg er i knipe, så finner jeg 
vanligvis veien ut. 
 
□ □ □ □ 
10. Samme hva som hender så er jeg 
vanligvis i stand til å takle det. □ □ □ □ 
 
Espen Røysamb (1997) [GSE] 
 
 
 
 
 
